Welcome to our dedicated page for Definium Therapeutics news (Ticker: DFTX), a resource for investors and traders seeking the latest updates and insights on Definium Therapeutics stock.
Definium Therapeutics, Inc. (Nasdaq: DFTX) is a New York-based biopharmaceutical company focused on psychedelic-inspired therapeutics for psychiatric and neurological disorders. The Definium Therapeutics news feed on Stock Titan aggregates company announcements and media releases so readers can follow how its clinical and corporate story develops over time.
According to the company, its late-stage pipeline centers on DT120 orally disintegrating tablet (ODT), which is in Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD). News items may include updates on the Voyage and Panorama studies in GAD, the Emerge and Ascend studies in MDD, and other milestones related to DT120 ODT, which the company reports has received FDA Breakthrough Therapy Designation for GAD.
Definium also reports an early-stage program, DT402, in a Phase 2a study for adults with autism spectrum disorder (ASD). Coverage can feature progress in this study, as well as broader pipeline developments and commentary on the company’s efforts to advance psychedelic-inspired medicines in psychiatry.
In addition to clinical updates, Definium Therapeutics news may highlight corporate developments such as its rebranding from Mind Medicine (MindMed) Inc., changes to its Nasdaq ticker symbol DFTX, and participation in industry conferences. Investors, analysts, and observers can use this page to review historical press releases and announcements that explain how Definium frames its mission to forge a new era of psychiatry and its plans to translate evidence into impact for patients.
Definium Therapeutics (NASDAQ:DFTX) announced inducement option grants to three newly hired non-executive employees totaling 88,850 options with effective grant dates of January 12 and January 26, 2025. The exercise price equals the closing price on each grant date. The options vest over four years with 25% on the first anniversary and the remaining 75% monthly over the next three years, subject to continued employment. The grants were approved by the company's Compensation Committee on January 8, 2026 under NASDAQ Rule 5635(c)(4) and were issued outside of Definium's equity incentive plans as material inducements to employment.
Definium Therapeutics (NASDAQ:DFTX) launched Rerouting Minds, an educational campaign to increase understanding of pharmaceutical lysergide (LSD) and the role of rigorous psychedelic research in mental health care. The campaign targets healthcare providers, psychiatrists, therapists, advocates, and policymakers and provides scientific context on LSD’s medical history (dating to 1938), hypothesized brain effects, and community resources. The release cites that nearly 1 in 4 adults (about 59.3 million in the U.S.) live with a mental health disorder and that over 28 million do not receive treatment. Materials and resources are available at www.definiumtx.com/rerouting-minds.
Definium Therapeutics (Nasdaq: DFTX) said its common shares will begin trading on Nasdaq under the new ticker DFTX effective at market open on January 15, 2026. The company previously expected the change on January 13, 2026 and updated the effective date to January 15. Shareholders do not need to take any action for the ticker symbol change.
Definium Therapeutics (NASDAQ:DFTX) announced a rebrand from MindMed and outlined a late-stage psychiatry program led by DT120 orally disintegrating tablet (ODT). The company expects three Phase 3 topline readouts in 2026: Voyage (1st GAD study) in 2Q, Panorama (2nd GAD study) in 2H, and Emerge (1st MDD study) mid-year. DT120 ODT holds FDA Breakthrough Therapy Designation for GAD. Definium plans FDA submissions for GAD and MDD markets, is preparing commercialization readiness, and continues early‑stage work, including dosing the first patient in a Phase 2a DT4023 study for ASD. The Nasdaq ticker changes to DFTX effective January 13, 2026, and the company will webcast a J.P. Morgan Healthcare Conference presentation on January 14, 2026.